DOCSLIB.ORG

ACG 2013! the Premier GI Clinical Event of the Year!

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
ACG 2013! the Premier GI Clinical Event of the Year! Welcome to ACG 2013! The Premier GI Clinical Event of the Year! Dear Colleagues, Welcome to ACG 2013, ACG’s Annual Scientific Meeting and Postgraduate Course, the premier GI clinical event of the year. The Postgraduate Course Directors and ACG’s Educational Affairs Committee, along with the Friday Course Directors, have brought together internationally recognized experts and rising stars in the field. This year’s program promises to deliver the latest clinical updates in gastroenterology and hepatology, plus discuss what is on the horizon that may impact your practice. Back by popular demand is the Hands-on Workshop Center. Located in the Exhibit Hall, we’ve included additional sessions this year. Seven of the 26 sessions offered are for GI fellows only. Pre-registration for any hands-on session is required. See the Hands-on Workshop Center counter at the ACG Registration Desk beginning Saturday, October 12th. For a complete list of sessions and times, see page 16. Hands-on sessions begin on Sunday, October 13th. 2013 was a record-breaking year for abstract submissions. You’ll find more than 1,700 posters and oral presentations this year. Poster presentations open on Sunday beginning at 3:30 pm. Posters may be found in the Exhibit Hall. A popular activity for viewing posters is Poster Rounds with the Experts. Each day of the poster sessions, well-known experts will lead attendees around to posters of interest. This is a great opportunity to discuss posters, garner insight from the experts, and make new contacts with other attendees in a low-key, relaxed environment. Poster Rounds with the Experts run from Sunday through Tuesday. Two workshops are added this year. On Monday, October 14th, from 12:45 pm – 2:15 pm the ACG-FDA Public Forum: Toward Improving the Quality of Colonoscopy: Evidence-based State of the Art in Bowel Preparation, will be held in Room 5AB. Learn more on page 57. Also on Monday, from 3:55 pm – 4:35 pm, in Room 5AB, a special workshop will be offered by the ABIM on new requirements beginning in 2014 regarding increased frequency of MOC credits. Learn the details of these changes and what it means to you when you attend. Limited seating is available for both workshops. Two social events are open to all attendees this year. The Exhibit Hall Opening Reception will take place on Sunday, October 13, from 5:15 pm – 7:00 pm, immediately following the Postgraduate Course. The largest social event at the meeting, it is a great opportunity to enjoy food and drink with colleagues and friends and to explore the Exhibit Hall in support of the meeting’s sponsors. Also this year is a light reception honoring the ACG President, in association with the ACG Annual Business Meeting, on Monday, October 14 beginning at 6:00 pm. Enjoy light snacks and drinks as we elect a new slate of officers. Join the leadership of the College and visit with your friends at these important collegial events. In closing, I want to thank you for the opportunity to serve you this year as ACG President. Your support has made the College more successful than ever. Sincerely, Ronald J. Vender, MD, FACG ACG President 1 Schedule at a Glance Friday, October 11 Sunday, October 13, continued 6:00 am – 8:00 pm Registration 12:20 pm – 1:35 pm Optional Learning Luncheons* (ticket required) Exhibit Hall Lobby See ticket for room assignment 6:30 am – 8:00 am Continental Breakfast 12:20 pm – 1:35 pm Trainees Luncheon* (ticket required) Outside course rooms Room 17B 7:00 am – 12:00 noon GI Pathophysiology Course 3:30 pm – 7:00 pm Exhibit Hall Opens Ballroom 6B Exhibit Halls A-C 7:30 am – 4:45 pm Practice Management Course 3:30 pm – 7:00 pm Hands-on Workshop Center Ballroom 6A Exhibit Halls A-C 7:30 am – 5:00 pm ASGE-Sponsored Endoscopy Course 3:30 pm – 7:00 pm Job Forum Ballroom 6C Exhibit Halls A-C 1:15 pm – 4:30 pm What’s New in GI Pharmacology Course 3:30 pm – 7:00 pm Poster Sessions Ballroom 6B Exhibit Halls A-C 2:00 pm – 6:00 pm ACG Store 5:15 pm – 6:00 pm Exhibitor Theater Ballroom Lobby Exhibit Halls A-C 5:15 pm – 7:30 pm Negotiation and Networking Skills Workshop* 5:15 pm – 6:00 pm ACG Mentoring Program Reception Room 11A Room 9 5:00 pm – 9:30 pm Recertification Preparation & Update Course 5:15 pm – 6:00 pm International Attendee Reception Ballroom 6D Room 10 5:15 pm – 6:00 pm Women and Minorities in GI Reception Room 11A 5:15 pm – 7:00 pm Opening Welcome Reception Exhibit Halls A-C Saturday, October 12 6:00 pm – 7:00 pm Alumni Receptions 7:00 am – 7:45 am Continental Breakfast See invitation for room assignment Ballroom Lobby 6:15 pm – 7:00 pm Exhibitor Theater 7:00 am – 5:15 pm Registration Exhibit Halls A-C Exhibit Hall Lobby 7:50 am – 5:00 pm Postgraduate Course Ballroom 6 8:00 am – 10:00 am Auxiliary Registration/Hospitality Suite Monday, October 14 Manchester Grand Hyatt - Ford Room 8:00 am – 5:00 pm ACG Store 6:00 am – 4:45 pm Registration Ballroom Lobby Exhibit Hall Lobby 10:00 am – 10:30 am David Sun Lecture 6:30 am – 7:45 am Optional Breakfast Sessions* (ticket required) Ballroom 6 See ticket for room assignment 12:20 pm – 1:35 pm Optional Learning Luncheons* (ticket required) 7:50 am – 6:00 pm Annual Scientific Meeting See ticket for room assignment Ballroom 6 12:20 pm – 1:35 pm Career Opportunities for Women in GI Luncheon* 8:00 am – 10:00 am Auxiliary Registration/Hospitality Suite Room 16A (ticket required) Manchester Grand Hyatt - Ford Room 8:00 am – 6:00 pm ACG Store 5:15 pm – 7:00 pm GI Jeopardy Ballroom Lobby Room 5AB 9:00 am – 9:30 am Presidential Address Ballroom 6 10:00 am – 4:30 pm Exhibit Hall Exhibit Halls A-C Sunday, October 13 10:00 am – 4:30 pm Hands-on Workshop Center Exhibit Halls A-C 6:30 am – 7:45 am Trainees' Forum with Continental Breakfast 10:00 am – 4:30 pm Job Forum Room 2 Exhibit Halls A-C 7:00 am – 7:45 am Continental Breakfast 10:30 am – 11:30 am Exhibitor Theater Ballroom Lobby Exhibit Halls A-C 7:00 am – 6:30 pm Registration 10:30 am – 4:00 pm Poster Sessions Exhibit Hall Lobby Exhibit Halls A-C 7:50 am – 5:00 pm Postgraduate Course 12:45 pm – 1:30 pm ACG Theater Ballroom 6 Exhibit Halls A-C 8:00 am – 10:00 am Auxiliary Registration/Hospitality Suite 12:45 pm – 2:15 pm Lunch Break Manchester Grand Hyatt - Ford Room Exhibit Halls A-C 8:00 am – 5:00 pm ACG Store Ballroom Lobby * Pre-registration required 2 Schedule at a Glance SCHEDULE ACG 2013 Monday, October 14, continued Wednesday, October 16 12:45 pm – 2:15 pm NP/PA Luncheon Session* 6:00 am – 12:15 pm Registration Room 4 Exhibit Hall Lobby 12:45 pm – 2:15 pm ACG-FDA Public Forum on Quality Colonoscopy 6:45 am – 8:15 am Optional Breakfast Sessions* (ticket required) Room 5AB See ticket for room assignment 1:45 pm – 2:15 pm Exhibitor Theater 8:00 am – 12:15 pm ACG Store Exhibit Halls A-C Ballroom Lobby 3:00 pm – 3:45 pm The American Journal of Gastroenterology Lecture 8:30 am – 12:15 pm Annual Scientific Meeting Ballroom 6C Ballroom 6 3:30 pm – 4:30 pm Exhibitor Theater 10:15 am – 10:45 am David Y. Graham Lecture Exhibit Halls A-C Ballroom 6B 3:55 pm – 4:35 pm ACG Informational Session – Changes to ABIM’s Maintenance of Certification Program Room 5AB 6:00 pm – 7:00 pm ACG Business Meeting and Reception to Honor the ACG President Ballroom 6A Download ACG 2013 slides to your Apple or Android smart device with eventScribe! Tuesday, October 15 Follow along with the presenter COURSE AVAILABLE ON 6:00 am – 5:00 pm Registration when you download slides Exhibit Hall Lobby 6:45 am – 8:15 am Optional Breakfast Sessions* (ticket required) using the eventScribe app by See ticket for room assignment CadmiumCD. The eventScribe 8:00 am – 10:00 am Auxiliary Registration/Hospitality Suite app, native to Apple and Android Manchester Grand Hyatt - Ford Room devices including Tablets, 8:00 am – 6:15 pm ACG Store Look for this symbol to Ballroom Lobby Phones, and Kindle Fire, can be see if eventScribe slide 8:30 am – 6:15 pm Annual Scientific Meeting downloaded and used on-site downloads are available. Ballroom 6 during the meeting. eventScribe lets you take 10:00 am – 10:30 am J. Edward Berk Distinguished Lecture Ballroom 6B notes next to each slide, highlight information and 10:00 am – 4:30 pm Exhibit Hall draw on each slide. Save your notes to reference Exhibit Halls A-C after the meeting. For ACG 2013, the College has 10:00 am – 4:30 pm Hands-on Workshop Center Exhibit Halls A-C expanded the eventScribe offering to even more 10:00 am – 4:30 pm Job Forum courses – look for the symbol above in this book. Exhibit Halls A-C 10:30 am – 11:30 am Exhibitor Theater Exhibit Halls A-C 10:30 am – 4:00 pm Poster Sessions Exhibit Halls A-C 12:45 pm – 1:15 pm Exhibitor Theater Exhibit Halls A-C 12:45 pm – 2:15 pm Lunch Break Exhibit Halls A-C 1:40 pm – 2:15 pm Exhibitor Theater 2013 Exhibit Halls A-C ACG 4:30 pm – 5:00 pm Emily Couric Memorial Lecture Ballroom 6B SAN DIEGO October 11-16, 2013 The Premier GI Clinical Meeting and Postgraduate Course 3 Event Locations Event Locations — Friday, October 11 page 6:30 am–8:00 am Continental Breakfast Outside course rooms 7:00 am–12:00 noon GI Pathophysiology Course* Ballroom 6B 41 7:30 am–4:45 pm Practice Management Course* Ballroom 6A 34 7:30 am–5:00 pm ASGE-sponsored Endoscopy Course* Ballroom 6C 37 1:15 pm–4:30 pm What’s New in GI Pharmacology Course* Ballroom 6B 43 5:15 pm–7:30 pm Negotiation and Networking Skills Workshop* Room 11A 19 Advance registration required.
Load more

Recommended publications
  • Malignant Peritoneal Mesothelioma: Clinical Aspects, and Therapeutic Perspectives
    REVIEW ARTICLE Annals of Gastroenterology (2018) 31, 1-11 Malignant peritoneal mesothelioma: clinical aspects, and therapeutic perspectives Stergios Boussiosa, Michele Moschettab, Afroditi Karathanasia, Alexandros K. Tsiourisc, Foivos S. Kanellosc, Konstantina Tatsid, Konstantinos H. Katsanose, Dimitrios K. Christodouloue Medway NHS Foundation Trust, Kent, UK; Sarah Cannon Research Institute, London, UK; University of Ioannina, Greece; General Hospital G. Hatzikosta, Ioannina, Greece Abstract Malignant peritoneal mesothelioma (MPM) is a rare disease with a wide clinical spectrum. It arises from the peritoneal lining and commonly presents with diffuse, extensive spread throughout the abdomen and, more rarely, metastatic spread beyond the abdominal cavity. Computed tomography, magnetic resonance imaging and positron-emission tomography are important diagnostic tools used for the preoperative staging of MPM. The definitive diagnosis is based on histopathological analysis, mainly via immunohistochemistry. In this regard, paired- box gene 8 negativity represents a useful diagnostic biomarker for differentiating MPM from ovarian carcinoma. In addition, BRCA1-associated protein-1 (BAP1) loss is specific to MPM and allows it to be distinguished from both benign mesothelial lesions and ovarian serous tumors. Cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) has become an increasingly important therapeutic approach, while systemic therapies are still being developed. Histology, Ki-67, completeness of cytoreduction,
    [Show full text]
  • Mesothelin's Role As a Biomarker and Therapeutic Target for Malignant
    cancers Review Hitting the Bull’s-Eye: Mesothelin’s Role as a Biomarker and Therapeutic Target for Malignant Pleural Mesothelioma Dannel Yeo 1,2,3 , Laura Castelletti 1,2,3 , Nico van Zandwijk 2,3,4 and John E. J. Rasko 1,2,3,5,* 1 Li Ka Shing Cell & Gene Therapy Program, The University of Sydney, Camperdown, NSW 2050, Australia; [email protected] (D.Y.); [email protected] (L.C.) 2 Faculty of Medicine and Health, The University of Sydney, Camperdown, NSW 2050, Australia; [email protected] 3 Cell and Molecular Therapies, Royal Prince Alfred Hospital, Sydney Local Health District (SLHD), Camperdown, NSW 2050, Australia 4 Concord Repatriation General Hospital, Sydney Local Health District (SLHD), Concord, NSW 2139, Australia 5 Gene and Stem Cell Therapy Program, Centenary Institute, The University of Sydney, Camperdown, NSW 2050, Australia * Correspondence: [email protected]; Tel.: +61-295656160 Simple Summary: Mesothelioma is a deadly disease with a dismal prognosis. Since its discovery, mesothelin, a cell surface protein, has been a promising biomarker and therapeutic target due to its overexpression in mesothelioma and limited expression in normal cells. This review summarizes the clinical studies that have examined mesothelin as a biomarker and therapeutic target in mesothelioma and explores future perspectives in its role to improve patient management. Abstract: Malignant pleural mesothelioma (MPM) is an aggressive cancer with limited treatment options and poor prognosis. MPM originates from the mesothelial lining of the pleura. Mesothelin Citation: Yeo, D.; Castelletti, L.; van (MSLN) is a glycoprotein expressed at low levels in normal tissues and at high levels in MPM.
    [Show full text]
  • Hospital Organ Donation Campaign Recognition for Outreach
    Hospital Organ Donation Campaign Recognition for Outreach The hospitals listed below reached gold, silver, and bronze recognition levels for their organ, eye, and tissue donation and registration efforts between August 1, 2014, and April 30, 2015. The hospitals worked closely with their organ procurement organizations and Donate Life America affiliates to educate and register new donors. In many states, the participation of state hospital associations was pivotal to the hospitals’ efforts. DLA and hospital association participation is indicated in the title line for each state. OPO participation is listed in the OPO recogni- tion list at the end of the document. SEARCH BY STATE: A B C D E F G H I J K L M N O P Q R S T U V W X Y Z OPO RECOGNITION ALABAMA • Donate Life Alabama 1 0 0 East Alabama Medical Center Y ARIZONA • Donate Life Arizona 3 11 28 • Arizona Hospital and Healthcare Association Abrazo Arizona Heart Hospital Y Abrazo Central Campus Y Abrazo Scottsdale Campus Y Abrazo West Campus Y American Liver Foundation Y Banner Boswell Medical Center Y Banner Casa Grande Regional Medical Center Y Banner Del E. Webb Medical Center Y Banner Desert Medical Center and Cardon Children’s Medical Center Y Banner Estrella Medical Center Y Banner Gateway Medical Center and Banner MD Anderson Cancer Center Y Banner Goldfield Medical Center Y Banner Ironwood Medical Center Y Banner Thunderbird Medical Center Y Banner University Medical Center—Tucson and South Campus* Y Barnet Dulaney Perkins Eye Center Y Carondelet St. Mary’s Hospital Y Chandler Regional Medical Center Y Cobre Valley Regional Medical Center Y Flagstaff Medical Center Y * denotes transplant centers 1 HonorHealth Deer Valley Medical Center Y HonorHealth John C.
    [Show full text]
  • (+232 Lbs ) KINGS of the RING WORLD SERIES
    OPEN SUPER HEAVYWEIGHT +105 kg (+232 lbs ) Japanese boxing - Shootboxing rules Super world champion Date, Place VACANT 14 World champion Date, Place VACANT Thai boxing - Full muaythai rules Thai boxing - International muaythai rules SUPER WORLD CHAMPION Date, Place SUPER WORLD CHAMPION Date, place VACANT VACANT WORLD CHAMPION Date, Place WORLD CHAMPION Date, Place 09.02.2008 LLOYD VAN DAMS ( NL ) 29.05.2004 TONY GREGORY ( FRA ) Auckland- = 289 pts Venice-ITA = 413 pts NZ OPBU EURO-AFRICAN CHAMPION Date, Place OPBU EURO-AFRICAN CHAMPION Date, Place VACANT VACANT Japanese boxing - K -1 rules Japanese boxing - Oriental Kick rules SUPER WORLD CHAMPION Date, Place SUPER WORLD CHAMPION Date, Place VACANT VACANT WORLD CHAMPION Date, Place WORLD CHAMPION Date, Place VACANT VACANT OPBU EURO-AFRICAN CHAMPION Date, Place OPBU EURO-AFRICAN CHAMPION Date, Place VACANT VACANT KINGS OF THE RING WORLD SERIES WIPU ORIENTAL PRO BOXING RULES SUPER WORLD CHAMPION Date, place VACANT e-mail : [email protected] mobile phone : +385 98 421 300 www.wipu-kings.com OPEN SUPER HEAVYWEIGHT +105 kg (+232 lbs ) 1. Semmy Schilt ( NL ) = 964 pts 2. Peter Aerts ( NL ) = 645 pts 3. Jerome Lebanner ( FRA ) = 571 pts 4. Alistar Overeem ( NL ) = 524 pts 5. Alexei Ignashov ( BLR ) = 432 pts 6. Daniel Ghita ( ROM ) = 362 pts 7. '' MIGHTY MO '' Siligia ( USA ) = 362 pts 8. Anderson '' Bradock '' Silva ( BRA ) = 344 pts 9. Mladen Brestovac ( CRO ) = 311 pts 10. Ismael Londt ( NL ) = 290 pts 11. Rico Verhoeven ( NL ) = 275 pts 12. Ben Edwards ( AUS ) = 258 pts 13. Peter Graham ( AUS ) = 243 pts 14. Alexandre Pitchkounov ( RUS ) = 236 pts 15.
    [Show full text]
  • UEMS 2020.11 Syllabus of the ETR in Rare Adult Cancers
    UNION EUROPÉENNE DES MÉDECINS SPÉCIALISTES EUROPEAN UNION OF MEDICAL SPECIALISTS Association internationale sans but lucratif International non-profit organisation RUE DE L’INDUSTRIE, 24 T +32 2 649 51 64 BE- 1040 BRUSSELS F +32 2 640 37 30 www.uems.eu [email protected] UEMS 2020.11 Syllabus for residents and trainees in Rare Adult Solid Cancers The basic goal of this syllabus is to provide an understanding between the instructor and trainee so there is minimal confusion in the topics, with clear expectations. It is not a classical syllabus as it contains descriptions from different areas, but it still summarizes major and specific topics that should be covered during the training course of a resident. This syllabus is intended as supporting reference material, and the precise content and priorities of training may vary in different training institutions. The syllabus can also be modified to reflect each instructor's teaching philosophy towards the trainees. 1. There are scientific publications, web pages, and conference materials available online that could be used for educational purposes for various types of rare adult solid cancers. This is a comprehensive summary of them. 2. There are significant differences in the number of available scientific publications and reviews for different rare adult solid cancers. Some, like sarcomas, have a very robust literature, while others have been sparsely researched and consequently the availability of study materials is quite poor. 3. These differences also apply to life events and natural history. In the list of the EU CE accredited events there is a strong underrepresentation for some types of rare adult solid cancers.
    [Show full text]
  • Ct Findings of Hypervascular Malignant Peritoneal Mesothelioma
    Compurerized Radial. Vol. I I, No. 2, pp. 91-94, 1987 0730-4862/87 53.00 + 0.00 Printed in the U.S.A. All rights reserved Copyright 8 1987 Pergamon Journals Ltd CT FINDINGS OF HYPERVASCULAR MALIGNANT PERITONEAL MESOTHELIOMA DEBORAH S. GRANKE,* JAMES H. ELLIS and BRUCE D. RICHMOND Radiology Service (114) Veterans Administration Medical Center and Department of Radiology. University of Michigan Medical School, Ann Arbor, MI 48105. U.S.A. (Received 19 June 1986; in revised form 21 October 1986; received for publicatiorr 6 November 1986) Abstract-A case of peritoneal mesothelioma is presented in which CT demonstrated abnormal regions of increased vascularity in the omentum corresponding to hypervascular omental lesions shown by angiography. This CT appearance has not been described in prior reports of CT in peritoneal mesothelioma. Mesothelioma. peritoneal Angiography Computed tomography INTRODUCTION Reports of computed tomography (CT) in mesothelioma describe peritoneal involvement that may be extensive, with confluent tumor in layers, masses, and/or nodules and mesenteric infiltration [l, 21. A recent report of anteriography in peritoneal mesothelioma described three cases of mildly to moderately hypervascular omental lesions without arteriovenous shunting; however, the one CT scan performed was nondiagnostic [3]. We report a case of peritoneal mesothelioma where CT demon- strated abnormal regions of increased vascularity in the omentum corresponding to the hypervascular omental lesions shown by angiography. CASE REPORT A 54-year-old white male presented with a 3-month history of insidious onset of diffuse abdominal tenderness, early satiety, abdominal bloating, and crampy abdominal pain. His physical exam was unremarkable, and routine laboratory tests, sigmoidoscopy, and barium enema were normal.
    [Show full text]
  • Antitumor Activity of Mir-34A in Peritoneal Mesothelioma Relies on C-MET and AXL Inhibition
    El Bezawy et al. Journal of Hematology & Oncology (2017) 10:19 DOI 10.1186/s13045-016-0387-6 RESEARCH Open Access Antitumor activity of miR-34a in peritoneal mesothelioma relies on c-MET and AXL inhibition: persistent activation of ERK and AKT signaling as a possible cytoprotective mechanism Rihan El Bezawy1, Michelandrea De Cesare1, Marzia Pennati1, Marcello Deraco2, Paolo Gandellini1, Valentina Zuco1*† and Nadia Zaffaroni1*† Abstract Background: The value of microRNAs (miRNAs) as novel targets for cancer therapy is now widely recognized. However, no information is currently available on the expression/functional role of miRNAs in diffuse malignant peritoneal mesothelioma (DMPM), a rapidly lethal disease, poorly responsive to conventional treatments, for which the development of new therapeutic strategies is urgently needed. Here, we evaluated the expression and biological effects of miR-34a—one of the most widely deregulated miRNAs in cancer and for which a lipid-formulated mimic is already clinically available—in a large cohort of DMPM clinical samples and a unique collection of in house-developed preclinical models, with the aim to assess the potential of a miR-34a-based approach for disease treatment. Methods: miR-34a expression was determined by qRT-PCR in 45 DMPM and 7 normal peritoneum specimens as well as in 5 DMPM cell lines. Following transfection with miR-34a mimic, the effects on DMPM cell phenotype, in terms of proliferative potential, apoptotic rate, invasion ability, and cell cycle distribution, were assessed. In addition, three subcutaneous and orthotopic DMPM xenograft models were used to examine the effect of miR-34a on tumorigenicity. The expression of miRNA targets and the activation status of relevant pathways were investigated by western blot.
    [Show full text]
  • Desmoplastic Small Round Cell Tumor of the Abdomen: a Case Report and Literature Review of Therapeutic Options
    Vol.4, No.4, 207-211 (2012) Health http://dx.doi.org/10.4236/health.2012.44031 Desmoplastic small round cell tumor of the abdomen: A case report and literature review of therapeutic options Hafida Benhammane1*, Leila Chbani2, Abdelmalek Ousadden3, Ouadii Mouquit3, Siham Tizniti4, Afaf Riffi Amarti2, Nouafal Mellas1, Omar El Mesbahi1 1Department of Medical Oncology, Hassan II University Hospital, Fez, Morocco; *Corresponding Author: [email protected] 2Department of Pathology, Hassan II University Hospital, Fez, Morocco 3Department of General Surgery, Hassan II University Hospital, Fez, Morocco 4Department of Radiology, Hassan II University Hospital, Fez, Morocco Received 22 December 2011; revised 18 January 2012; accepted 6 February 2012 ABSTRACT rent therapeutic options include multiagent chemothe- rapy and aggressive surgical debulking and radiotherapy Desmoplastic small round cell tumor (DSRCT) is [4,5]. The addition of hyperthermic intra-peritoneal che- a rare and highly aggressive variety of sarcoma motherapy in the multimodal approach has been reported arising typically from abdominal or pelvic peri- in very few cases but no effect on survival has been clearly toneum. Diagnosis and treatment approaches of demonstrated [6]. this entity are complex and require a skilled, ex- The prognosis of this disease is poor with a Median perienced, multidisciplinary team. Authors re- survival of 17 months approximately [7]. port their experience with a case of an intra-ab- We report a case of an intra-abdominal DSRCT in a 37 dominal DSRCT arising in a 37-year-old young -year-old young man who was treated with combination man in order to discuss the clinico-pathological chemotherapy and surgery.
    [Show full text]
  • Tenet Healthcare Annual Report 2021
    Tenet Healthcare Annual Report 2021 Form 10-K (NYSE:THC) Published: February 19th, 2021 PDF generated by stocklight.com UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-K ☒ Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the fiscal year endedD ecember 31, 2020 OR ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the transition period from to Commission File Number 1-7293 ________________________________________ TENET HEALTHCARE CORPORATION (Exact name of Registrant as specified in its charter) Nevada 95-2557091 (State of Incorporation) (IRS Employer Identification No.) 14201 Dallas Parkway Dallas, TX 75254 (Address of principal executive offices, including zip code) (469) 893-2200 (Registrant’s telephone number, including area code) ________________________________________________________ Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading symbol Name of each exchange on which registered Common stock, $0.05 par value THC New York Stock Exchange 6.875% Senior Notes due 2031 THC31 New York Stock Exchange Securities registered pursuant to Section 12(g) of the Act: None ________________________________________________________ Indicate by check mark if the Registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes x No ¨ Indicate by check mark if the Registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Exchange Act. Yes ¨ No x Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the preceding 12 months, and (2) has been subject to such filing requirements for the past 90 days.
    [Show full text]
  • "Gastrointestinal Tract Pathology"
    IIC,J CALIFORNIA TUMOR TISSUE REGISTRY "GASTROINTESTINAL TRACT PATHOLOGY" Study Cases, Subscription A March 2000 California Tumor Tissue Registry c/o: De1mrtment of Pathology and Human Anatomy Loma Linda Univcr.;ily School ofMcd.icine 11021 Campus Avenue, AH 335 Lomn Linda, California 92350 (909) 558-4788 FAX: (909) 558·0188 E-mail: [email protected] Case oftbe Month: www.llu.edu/Uu/cttr/cotm Target audience: Practicing pathologists and pathology residents. Goal: To acquairu the participam with the hiswlogic featu res of a variety of benign and malignant neoplasms and tumor-l ike conditions. Objectives: n1e participant will be able to recognize morphologic features ofa variety of benign and malignam neoplasms and tWllOr-like conditions and relate those processes to pertinent references in d1e medical literature. Educational methods and media: Review of representative glass slides v.ith associated histories. Feedback on consensus diagnoses lt·om participating pathologists. Listing of selected references from the medical literature. Principal faculty: Weldon K. Bullock, Ml) Donald R. Chase, MD CME Credit: Lorna Li.nda University School of Medicine designates this continuing medical education·activity for up to 2 hours of Category I of the Physician's Recogn ition Award oft he· American Medical Association. CME credit is offered for d1e subscription year only. Accreditation: Loma Linda University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to sponsor continuing medical education for physicians. Contributor: James A. Henry, M.D. Case No. 1 - March 2000 Woodbridge, VA Tissue from: Terminal ileum Accession #28502 Clinical Abstract: This 37-year-old black female presented with several weeks' history of right lower quadrant abdominal pain radiating to the right side of the back and right inguinal area.
    [Show full text]
  • Your Guide to Top Care
    2019 EDITION Exclusive Rankingskings How Hospitalss YOUR Are Battling thehe GUIDE Opioid Epidemicemic TO TOP Surgery Ahead?head? CARE Ask These Questionsestions Why STRENGTH TRAINING Really Matterss PLUS: America’s Healthiest Communities It’s Time to Plan Ahead Every 40 seconds, someone in America has a stroke or a heart attack.ck. Chances are it could be you or someone you love. That’s why it’s crucial to researchh the best options for receiving heart and stroke care before thee ttimeime comes when you need it. Each year, the American Heart Association recognizes hospitals that demonstrate a high commitment to following guidelines that improve patient outcomes. Read more about the award categories and locate a participating hospital near you. From 2005 to 2015 Currently, more More than 7 million the annual death than 2,500 hospitals people have been rate attributable to participate in at least treated through our coronary heart one American Heart hospital-based disease declined 34.4 Association quality quality initiatives percent. The number initiative module. since the first of deaths declined Many participate in one was launched 17.7 percent. two or more. in 2000. ISTOCK © 2018 American Heart Association SPONSORED CONTENT Key to the Awards Gold Achievement A A A A Silver Achievement C C C C These hospitals are recognized for two or more consecutive These hospitals are recognized for one calendar year of calendar years of 85% or higher adherence on all 85% or higher adherence on all achievement measures achievement measures applicable
    [Show full text]
  • The Hospitals Listed Here Push Hard to Make Sure Their Heart Disease and Stroke Patients Get the Benefits of Up-To-Date Scientific Guidelines-Based Treatment
    WHEN HOSPITALS GO THE EXTRA MILE, PATIENTS DO TOO The hospitals listed here push hard to make sure their heart disease and stroke patients get the benefits of up-to-date scientific guidelines-based treatment. How? By actively participating in our healthcare quality programs. We thank them for all they do to get patients back on track. One day, you might too. Learn more at Heart.org/USNWR2015. A BIG THANKS TO OUR SPONSORS We appreciate these sponsors for funding our healthcare quality programs and for respecting our clinical independence. AWARD LEVELS SILVER ACHIEVEMENT These hospitals are recognized for 12 consecutive months of 85% or higher adherence on all achievement measures applicable to atrial fibrillation (AFIB) GOLD PLUS ACHIEVEMENT GOLD ACHIEVEMENT SILVER PLUS ACHIEVEMENT SILVER ACHIEVEMENT These hospitals are recognized for two These hospitals are These hospitals are recognized for These hospitals are or more consecutive years of 85% or recognized for two or more 12 consecutive months of 85% or recognized for 12 consecutive higher adherence on all achievement consecutive years of 85% higher adherence on all achievement months of 85% or higher measures applicable and 75% or higher or higher adherence on all measures applicable and 75% or higher adherence on all achievement adherence with four or more select achievement measures adherence with four or more select measures applicable to heart quality measures in heart failure (HF) applicable to heart failure (HF) quality measures in heart failure (HF) failure (HF) GOLD ACHIEVEMENT
    [Show full text]